News
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...
The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback